Recent Posts

Pages: [1] 2 3 ... 10
1
OCREVUS (ocrelizumab) / NEPAD and Ocrevus
« Last post by agate on Today at 07:47:49 am »
This article is mainly pharma company promotion for Ocrevus but includes a discussion of a new standard being used to assess MS disease progression, NEPAD (no evidence of progression or active disease). From Multiple Sclerosis News Today, February 19, 2018:


https://multiplesclerosisnewstoday.com/2018/02/19/ocrevus-data-actrims-2018-reinforces-benefit-rrms-ppms-genetech-garren-interview/
2
From PubMed, February 18, 2018:


https://www.ncbi.nlm.nih.gov/pubmed/29449827 [includes a link to the entire article]



Quote
Front Neurol. 2018 Feb 1;9:16.Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course.
Simpson S Jr.
[size=0.8461em]1,[/size][size=0.8461em]2[/size], van der Mei I[size=0.8461em]1[/size], Lucas RM[size=0.8461em]3,[/size][size=0.8461em]4[/size], Ponsonby AL[size=0.8461em]3,[/size][size=0.8461em]5,[/size][size=0.8461em]6[/size], Broadley S[size=0.8461em]7[/size], Blizzard L[size=0.8461em]1[/size]; Ausimmune/AusLong Investigators Group, Taylor B[size=0.8461em]1[/size].
[size=1.0769em]
Author information
[/size]1[/font][/color][/size][size=1.0769em][/color][/size]Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.[/color][/size][size=1.0769em][/size]2[/color][/size]Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.[/color][/size]3[/color][/size]National Centre for Epidemiology and Population Health, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, ACT, Australia.[/color][/size]4[/color][/size]Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Australia.[/color][/size]5[/color][/size]Murdoch Children's Research Institute, Melbourne, VIC, Australia.[/color][/size]6[/color][/size]Royal Melbourne Hospital, School of Medicine, University of Melbourne, Melbourne, VIC, Australia.[/color][/size]7[/color][/size]School of Medicine, Griffith University, Gold Coast, QLD, Australia.[/color]

[/size][size=1.0769em]
Abstract
[/size]BACKGROUND:Low vitamin D and/or sun exposure have been associated with increased risk of multiple sclerosis (MS) onset. However, comparatively, few studies have prospectively examined associations between these factors and clinical course.OBJECTIVES:To evaluate the association of sun exposure parameters and vitamin D levels with conversion to MS and relapse risk in a prospectively monitored cohort of 145 participants followed after a first demyelinating event up to 5-year review (AusLong Study).METHODS:Sun exposure prior to and after onset measured by annual questionnaire; ultraviolet radiation (UVR) "load" estimated by location of residence over the life course and ambient UVR levels. Serum 25-hydroxyvitamin D [25(OH)D] concentrations measured at baseline, 2/3-year, and 5-year review. MS conversion and relapse assessed by neurologist assessment and medical record review.RESULTS:Over two-thirds (69%) of those followed to 5-year review (100/145) converted to MS, with a total of 252 relapses. Higher pre-MS onset sun exposure was associated with reduced risk of MS conversion, with internal consistency between measures and dose-response relationships. Analogous associations were also seen with risk of relapse, albeit less strong. No consistent associations were observed between postonset sun exposure and clinical course, however. Notably, those who increased their sun exposure during follow-up had significantly reduced hazards of MS conversion and relapse. Serum 25(OH)D levels and vitamin D supplementation were not associated with conversion to MS or relapse hazard.CONCLUSION:We found that preonset sun exposure was protective against subsequent conversion to MS and relapses. While consistent associations between postonset sun exposure or serum 25(OH)D level and clinical course were not evident, possibly masked by behavior change, those participants who markedly increased their sun exposure demonstrated a reduced MS conversion and relapse hazard, suggesting beneficial effects of sun exposure on clinical course.
[/size]
[size=1.0769em][/size]
3

"Flu vaccine effectiveness estimated at 36%"--from NEJM Journal Watch, February 16, 2018: :(

https://www.jwatch.org/fw113856/2018/02/16/flu-vaccine-effectiveness-estimated-36?query=pfwRSTOC&jwd=000100983645&jspc=
4
GENERAL DISCUSSION - RESEARCH, NEWS / (Abst.) Bryostatin-1 alleviates experimental MS
« Last post by agate on February 15, 2018, 09:34:57 am »
Abstract of "Bryostatin-1 alleviates experimental multiple sclerosis" by several Johns Hopkins researchers and published in PNAS (Proceedings of the National Academy of Sciences). From PubMed, February 15, 2018:


https://www.ncbi.nlm.nih.gov/pubmed/29440425


From the abstract:


Quote
More strikingly, bryo-1 reverses neurologic deficits after EAE onset, even when treatment is initiated at a late stage of disease when peak adaptive immunity has subsided.
And:

Quote
These findings suggest the potential for bryo-1 as a therapeutic agent in MS, particularly given its established clinical safety. Furthermore, the benefit of bryo-1, even in late treatment of EAE, combined with its targeting of innate myeloid cells suggests therapeutic potential in progressive forms of MS.

5
"Multiple sclerosis:  What's it got to do with your guts?" from The Lancet, March 2018:


http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30468-4/fulltext?elsca1=etoc
6
THE PRACTICAL SIDE OF BEING MULTIPLY SCLEROSED / About nurse practitioners
« Last post by agate on February 14, 2018, 06:31:31 am »
The current issue of Neurology Now has a brief article about nurse practitioners. What they can and can't do differs from state to state:


https://journals.lww.com/neurologynow/Fulltext/2018/14010/You_Ask__We_Answer___My_doctor_s_office_offers.13.aspx
7

The results of a survey done by the Accelerated Cure Project, entitled "Experiences and Opinions about Research:  Results from a Survey of People with MS--January 5, 2018" and with a special focus on racial and ethnic minorities, can be seen here:

https://www.acceleratedcure.org/sites/default/files/images/SurveyReport.pdf
8
TREATMENTS / (Abst.) Rituximab and other treatment choices for MS
« Last post by agate on February 12, 2018, 04:07:56 pm »
From JAMA Neurology, January 8, 2018, the abstract of an article entitled "Comparative effectiveness of rituximab and other treatment initial treatment choices for multiple sclerosis" by Granqvist et al. (Sweden):


https://jamanetwork.com/journals/jamaneurology/article-abstract/2668462?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert&utm_term=mostread&utm_content=olf-widget_02122018&redirect=true
9

I ran across this .pdf file, which comes from the National MS Society, probably one of the regional offices, and is labelled "LTC Training Handout." I'm guessing that it is meant to be distributed to staff members at long-term care facilities to assist them in dealing with patients with MS.  It is called "10 Hints for Quality Care of Residents with MS" but has some suggestions that would be useful to anyone with MS.

https://www.nationalmssociety.org/NationalMSSociety/media/Greater-Northwest/Resources/Files/LTC_Training_Handout.pdf
10
There seems to be curiosity about those patients on Tysabri who developed PML. Not much is ever disclosed about them but this presentation at the recent ACTRIMS conference discusses a few with PML who were treated with a combination of drugs:


https://multiplesclerosisnewstoday.com/2018/02/09/ms-related-study-shows-combo-therapy-can-keep-pml-infection-from-worsening/


From Multiple Sclerosis News Today (February 9, 2018), "#ACTRIMS2018: Combo can stop Tysabri-related PML infection from worsening, study shows"
Pages: [1] 2 3 ... 10